Is There a Clinically Significant Interaction Between Calcium Channel Antagonists and Clopidogrel? | Zendy

Christopher W. Good | Zendy; Steven R. Steinhubl | Zendy; Danielle M. Brennan | Zendy; A. Michael Lincoff | Zendy; Eric J. Topol | Zendy; Peter B. Berger | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Is There a Clinically Significant Interaction Between Calcium Channel Antagonists and Clopidogrel?

Author(s) -

Christopher W. Good,

Steven R. Steinhubl,

Danielle M. Brennan,

A. Michael Lincoff,

Eric J. Topol,

Peter B. Berger

Publication year - 2012

Publication title -

circulation cardiovascular interventions

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.621

H-Index - 95

eISSN - 1941-7632

pISSN - 1941-7640

DOI - 10.1161/circinterventions.111.963405

Subject(s) - clopidogrel , medicine , percutaneous coronary intervention , myocardial infarction , ticlopidine , anesthesia , post hoc analysis , pharmacology , cardiology

Clopidogrel is an inactive prodrug; it is converted to its active metabolite through the cytochrome P450 (CYP3A4) pathway, which also metabolizes calcium channel blockers (CCBs). Several studies have reported that CCBs reduce the ability of clopidogrel to inhibit platelet aggregability; one suggested that CCBs reduce the efficacy of clopidogrel.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research